4
Changes in Ownership
IONIS PHARMACEUTICALS INC Filed Acc 0000874015-26-000208
EVP, Chief Development Officer sold 60,846 shares at an average $73.41 ($4,466,428)
- EVP, Chief Development Officer acquired 60,846 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Kordasiewicz Holly B. · EVP, Chief Development Officer
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-06-12 | Exercise or conversion : show line 1 in the form 10b5-1 | +7,951 | $60.89 | $484,136 | 30,409 | D |
| 2026-06-12 | Exercise or conversion : show line 2 in the form 10b5-1 | +21,000 | $60.89 | $1,278,690 | 51,409 | D |
| 2026-06-12 | Exercise or conversion : show line 3 in the form 10b5-1 | +12,000 | $32.60 | $391,200 | 63,409 | D |
| 2026-06-12 | Exercise or conversion : show line 4 in the form 10b5-1 | +19,895 | $56.78 | $1,129,638 | 83,304 | D |
| 2026-06-12 | Sale : show line 5 in the form 10b5-1 | −41,004 | $73.09 | $2,997,122 | 42,300 | D |
| 2026-06-12 | Sale : show line 6 in the form 10b5-1 | −19,842 | $74.05 | $1,469,306 | 22,458 | D |
| Open-market sales · 60,846 sh · avg $73.41 · $4,466,428 | ||||||
Table II: Derivative
4 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-06-12 | Exercise or conversion : show line 7 in the form 10b5-1 Non-Qualified Stock Option (right to buy) | −12,000 | 0 | D |
| 2026-06-12 | Exercise or conversion : show line 8 in the form 10b5-1 Non-Qualified Stock Option (right to buy) | −19,895 | 0 | D |
| 2026-06-12 | Exercise or conversion : show line 9 in the form 10b5-1 Non-Qualified Stock Option (right to buy) | −7,951 | 21,000 | D |
| 2026-06-12 | Exercise or conversion : show line 10 in the form 10b5-1 Non-Qualified Stock Option (right to buy) | −21,000 | 0 | D |
Loading xslF345X06/edgardoc.xml…